New hope for ER+ breast cancer patients
A recent breakthrough in breast cancer research has uncovered a significant development in the fight against the disease. Scientists have identified how to effectively eliminate 'hibernating' tumour cells, potentially paving the way for new treatments to prevent cancer recurrence.
Understanding the mechanism behind cancer recurrence
Patients with oestrogen receptor-positive (ER+) breast cancer, which accounts for 80% of all breast cancer cases, may benefit from this groundbreaking discovery. By delving into the process of cancer cell dormancy and reactivation, researchers aim to provide a solution that reduces the risk of cancer returning.
Key findings and potential implications
The study, published in the journal Cancer Discovery, focused on inhibiting an enzyme called G9a to prevent cancer cells from entering a dormant state and to effectively target those already hibernating. This innovative approach opens up new possibilities for developing treatments that could significantly impact cancer recurrence rates.
Potential for future treatments
Dr. Tayyaba Jiwani, a science engagement manager at Cancer Research UK, highlighted the importance of this research in uncovering the genetic mechanisms behind cancer cell dormancy. The findings offer promising targets for the development of innovative treatments that could help prevent breast cancer from resurfacing.
